These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25535979)

  • 21. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
    J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
    J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methionine restriction reduces the chemosensitivity of central nervous system tumour cell lines.
    Najim N; Podmore ID; McGown A; Estlin EJ
    Anticancer Res; 2009 Aug; 29(8):3103-8. PubMed ID: 19661322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhancement of glioblastoma cell killing by combination treatment with temozolomide and tamoxifen or hypericin.
    Gupta V; Su YS; Wang W; Kardosh A; Liebes LF; Hofman FM; Schönthal AH; Chen TC
    Neurosurg Focus; 2006 Apr; 20(4):E20. PubMed ID: 16709026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
    Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
    Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
    Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling.
    Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J
    Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HFE polymorphisms influence the response to chemotherapeutic agents via induction of p16INK4A.
    Lee SY; Liu S; Mitchell RM; Slagle-Webb B; Hong YS; Sheehan JM; Connor JR
    Int J Cancer; 2011 Nov; 129(9):2104-14. PubMed ID: 21190189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
    Hsu CY; Lin SC; Ho HL; Chang-Chien YC; Hsu SP; Yen YS; Chen MH; Guo WY; Ho DM
    Am J Surg Pathol; 2013 Feb; 37(2):264-71. PubMed ID: 23282970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts.
    Kitange GJ; Carlson BL; Schroeder MA; Grogan PT; Lamont JD; Decker PA; Wu W; James CD; Sarkaria JN
    Neuro Oncol; 2009 Jun; 11(3):281-91. PubMed ID: 18952979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications.
    Zhang J; Stevens MF; Laughton CA; Madhusudan S; Bradshaw TD
    Oncology; 2010; 78(2):103-14. PubMed ID: 20357518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MGMT methylation: a marker of response to temozolomide in low-grade gliomas.
    Everhard S; Kaloshi G; Crinière E; Benouaich-Amiel A; Lejeune J; Marie Y; Sanson M; Kujas M; Mokhtari K; Hoang-Xuan K; Delattre JY; Thillet J
    Ann Neurol; 2006 Dec; 60(6):740-3. PubMed ID: 17192931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro drug response and molecular markers associated with drug resistance in malignant gliomas.
    Fruehauf JP; Brem H; Brem S; Sloan A; Barger G; Huang W; Parker R
    Clin Cancer Res; 2006 Aug; 12(15):4523-32. PubMed ID: 16899598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Folate supplementation limits the aggressiveness of glioma via the remethylation of DNA repeats element and genes governing apoptosis and proliferation.
    Hervouet E; Debien E; Campion L; Charbord J; Menanteau J; Vallette FM; Cartron PF
    Clin Cancer Res; 2009 May; 15(10):3519-29. PubMed ID: 19451595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of protracted daily temozolomide for low-grade gliomas in adults.
    Kesari S; Schiff D; Drappatz J; LaFrankie D; Doherty L; Macklin EA; Muzikansky A; Santagata S; Ligon KL; Norden AD; Ciampa A; Bradshaw J; Levy B; Radakovic G; Ramakrishna N; Black PM; Wen PY
    Clin Cancer Res; 2009 Jan; 15(1):330-7. PubMed ID: 19118062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological activity of tumor-treating fields in preclinical glioma models.
    Silginer M; Weller M; Stupp R; Roth P
    Cell Death Dis; 2017 Apr; 8(4):e2753. PubMed ID: 28425987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re-evaluation of cytostatic therapies for meningiomas in vitro.
    Wilisch-Neumann A; Pachow D; Wallesch M; Petermann A; Böhmer FD; Kirches E; Mawrin C
    J Cancer Res Clin Oncol; 2014 Aug; 140(8):1343-52. PubMed ID: 24816784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repositioning chlorpromazine for treating chemoresistant glioma through the inhibition of cytochrome c oxidase bearing the COX4-1 regulatory subunit.
    Oliva CR; Zhang W; Langford C; Suto MJ; Griguer CE
    Oncotarget; 2017 Jun; 8(23):37568-37583. PubMed ID: 28455961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined Delivery of Temozolomide and Anti-miR221 PNA Using Mesoporous Silica Nanoparticles Induces Apoptosis in Resistant Glioma Cells.
    Bertucci A; Prasetyanto EA; Septiadi D; Manicardi A; Brognara E; Gambari R; Corradini R; De Cola L
    Small; 2015 Nov; 11(42):5687-95. PubMed ID: 26395266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway.
    Oliveira-Ferrer L; Hauschild J; Fiedler W; Bokemeyer C; Nippgen J; Celik I; Schuch G
    J Exp Clin Cancer Res; 2008 Dec; 27(1):86. PubMed ID: 19114005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.